US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Apellis Pharmaceuticals Inc (APLS)
Apellis Pharmaceuticals Inc (APLS) ニュース

APLS

Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:APLS

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/24	23 : 00	GlobeNewswire Inc.	Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/05/22	05 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/05/14	21 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/05/14	21 : 00	GlobeNewswire Inc.	Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/05/10	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/05/09	06 : 13	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/05/07	20 : 05	GlobeNewswire Inc.	Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/05/07	20 : 02	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/05/06	20 : 00	GlobeNewswire Inc.	Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/05/01	20 : 00	GlobeNewswire Inc.	Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/04/26	20 : 15	GlobeNewswire Inc.	Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/04/23	20 : 00	GlobeNewswire Inc.	Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/04/05	05 : 05	GlobeNewswire Inc.	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/04/01	20 : 00	GlobeNewswire Inc.	Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/12	05 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/11	20 : 00	GlobeNewswire Inc.	Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/09	06 : 10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/08	21 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/07	06 : 05	GlobeNewswire Inc.	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/06	06 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/06	06 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/02	06 : 25	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/02	03 : 37	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/03/01	07 : 10	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/02/27	21 : 35	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/02/27	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/02/27	21 : 05	GlobeNewswire Inc.	Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/02/27	21 : 01	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/02/26	21 : 00	GlobeNewswire Inc.	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences	NASDAQ:APLS	Apellis Pharmaceuticals Inc
2024/02/20	21 : 00	GlobeNewswire Inc.	Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:APLS	Apellis Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:APLS

1 2 3 4 5 6 7 8 9 10 次へ >>

Le Banque Postale Zero C...

Investec Bnk 28

BNP Paribas Issuance

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約